Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
Titel:
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
Auteur:
Martin, Miguel Roche, Henri Pinter, Tamas Crown, John Kennedy, M John Provencher, Louise Priou, Frank Eiermann, Wolfgang Adrover, Encarna Lang, Istvan Ramos, Manuel Latreille, Jean Jagiełło-Gruszfeld, Agnieszka Pienkowski, Tadeusz Alba, Emilio Snyder, Raymond Almel, Sachin Rolski, Janusz Munoz, Montserrat Moroose, Rebecca Hurvitz, Sara Baños, Ana Adewoye, Henry Hei, Yong-Jiang Lindsay, Mary-Ann Rupin, Matthieu Cabaribere, David Lemmerick, Yasmin Mackey, John R